A Dose Escalating Phase Ia-b Clinical Trial of the IGF-1 Receptor Inhibitor AXL1717 in Patients With Advanced Cancer: A Prospective, Single Armed, Open Label, Dose-finding Phase Ia-b Study.

Trial Profile

A Dose Escalating Phase Ia-b Clinical Trial of the IGF-1 Receptor Inhibitor AXL1717 in Patients With Advanced Cancer: A Prospective, Single Armed, Open Label, Dose-finding Phase Ia-b Study.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Jan 2016

At a glance

  • Drugs Picropodophyllin (Primary)
  • Indications Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 02 Jun 2012 Data from this trial has been presented in a poster presentation at the Annual Meeting of the Americal Society of Clinical Oncology (ASCO) according to an Axelar AB media release.
    • 15 May 2012 Data from this trial will be included in a poster presentation at the Annual Meeting of the Americal Society of Clinical Oncology (ASCO) in June 2012.
    • 29 Mar 2011 Results from the phase I part in patients with squamous cell lung cancer will be presented at the 102nd Annual Meeting of the American Association for Cancer Research (abstract # 1276).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top